Natriuretic peptide receptor-3 underpins the disparate regulation of endothelial and vascular smooth muscle cell proliferation by C-type natriuretic peptide

British Journal of Pharmacology

Volumn 164, Issue 2 B, 2011, Pages 584-597

  Khambata, Rayomand S ^a   Panayiotou, Catherine M ^a   Hobbs, Adrian J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

atherosclerosis; C type natriuretic peptide; endothelial cell; extracellular signal regulated kinase; knockout mice; natriuretic peptide receptor C; restenosis; vascular smooth muscle cell

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NATRIURETIC PEPTIDE RECEPTOR 3; NATRIURETIC PEPTIDE TYPE C; RECEPTOR; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; CELL CULTURE; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENDOTHELIAL SMOOTH MUSCLE CELL; ENZYME ACTIVATION; IN VITRO STUDY; KNOCKOUT MOUSE; MITOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULAR SMOOTH MUSCLE CELL;

ANIMALS; AORTA; CELL CYCLE PROTEINS; CELL GROWTH PROCESSES; CELLS, CULTURED; CYCLIC GMP; CYCLIN D1; ENDOTHELIAL CELLS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLAVONOIDS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; MICE; MICE, KNOCKOUT; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NATRIURETIC PEPTIDE, C-TYPE; OLIGOPEPTIDES; PHOSPHORYLATION; QUINOXALINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ATRIAL NATRIURETIC FACTOR; SIGNAL TRANSDUCTION;

EID: 80052216593     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01400.x     Document Type: Article

References (67)

1. Ahluwalia A, Hobbs AJ, (2005). Endothelium-derived C-type natriuretic peptide: more than just a hyperpolarizing factor. Trends Pharmacol Sci 26: 162-167. (Pubitemid 40313596)
2. Ahluwalia A, MacAllister RJ, Hobbs AJ, (2004). Vascular actions of natriuretic peptides. Cyclic GMP-dependent and -independent mechanisms. Basic Res Cardiol 99: 83-89. (Pubitemid 38325021)
3. Alexander SPH, Mathie A, Peters JA, (2009). Guide to Receptors and Channels (GRAC), 4th edn. Br J Pharmacol 158 (Suppl. 1): S1-S254.
4. Anand-Srivastava MB, Sehl PD, Lowe DG, (1996). Cytoplasmic domain of natriuretic peptide receptor-C inhibits adenylyl cyclase. Involvement of a pertussis toxin-sensitive G protein. J Biol Chem 271: 19324-19329. (Pubitemid 26271602)
5. Baliga RS, Zhao L, Madhani M, Lopez-Torondel B, Visintin C, Selwood D, et al,. (2008). Synergy between natriuretic peptides and phosphodiesterase 5 inhibitors ameliorates pulmonary arterial hypertension. Am J Respir Crit Care Med 178: 861-869.
6. Bauer PM, Buga GM, Ignarro LJ, (2001). Role of p42/p44 mitogen-activated-protein kinase and p21waf1/cip1 in the regulation of vascular smooth muscle cell proliferation by nitric oxide. Proc Natl Acad Sci USA 98: 12802-12807. (Pubitemid 33020025)
7. Bourassa MG, (1994). Long-term vein graft patency. Curr Opin Cardiol 9: 685-691. (Pubitemid 24341158)
8. Cahill PA, Hassid A, (1994). ANF-C-receptor-mediated inhibition of aortic smooth muscle cell proliferation and thymidine kinase activity. Am J Physiol 266: R194-R203.
9. Chamley-Campbell J, Campbell GR, Ross R, (1979). The smooth muscle cell in culture. Physiol Rev 59: 1-61. (Pubitemid 9106924)
10. Chauhan SD, Nilsson H, Ahluwalia A, Hobbs AJ, (2003). Release of C-type natriuretic peptide accounts for the biological activity of endothelium-derived hyperpolarizing factor. Proc Natl Acad Sci USA 100: 1426-1431. (Pubitemid 36184018)
11. Chen HH, Burnett JC, Jr, (1998). C-type natriuretic peptide: the endothelial component of the natriuretic peptide system. J Cardiovasc Pharmacol 32 (Suppl. 3): S22-S28. (Pubitemid 29019748)
12. Connelly L, Jacobs AT, Palacios-Callender M, Moncada S, Hobbs AJ, (2003). Macrophage endothelial nitric-oxide synthase autoregulates cellular activation and pro-inflammatory protein expression. J Biol Chem 278: 26480-26487. (Pubitemid 36876789)
13. Doi K, Ikeda T, Itoh H, Ueyama K, Hosoda K, Ogawa Y, et al,. (2001). C-type natriuretic peptide induces redifferentiation of vascular smooth muscle cells with accelerated reendothelialization. Arterioscler Thromb Vasc Biol 21: 930-936. (Pubitemid 34168648)
14. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, et al,. (1994). A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 331: 496-501. (Pubitemid 24256752)
15. Fitzgibbon GM, Kafka HP, Leach AJ, Keon WJ, Hooper GD, Burton JR, (1996). Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol 28: 616-626. (Pubitemid 26288642)
16. Fu XD, Cui YH, Lin GP, Wang TH, (2007). Non-genomic effects of 17beta-estradiol in activation of the ERK1/ERK2 pathway induces cell proliferation through upregulation of cyclin D1 expression in bovine artery endothelial cells. Gynecol Endocrinol 23: 131-137.
17. Furuya M, Yoshida M, Hayashi Y, Ohnuma N, Minamino N, Kangawa K, et al,. (1991). C-type natriuretic peptide is a growth inhibitor of rat vascular smooth muscle cells. Biochem Biophys Res Commun 177: 927-931.
18. Furuya M, Aisaka K, Miyazaki T, Honbou N, Kawashima K, Ohno T, et al,. (1993). C-type natriuretic peptide inhibits intimal thickening after vascular injury. Biochem Biophys Res Commun 193: 248-253. (Pubitemid 23199939)
19. Gether U, (2000). Uncovering Molecular Mechanisms Involved in Activation of G Protein-Coupled Receptors. Endocr Rev 21: 90-113. (Pubitemid 32260396)
20. Gudermann T, Nurnberg B, Schultz G, (1995). Receptors and G proteins as primary components of transmembrane signal transduction. Part 1. G-protein-coupled receptors: structure and function. J Mol Med 73: 51-63.
21. Hallak H, Seiler AE, Green JS, Ross BN, Rubin R, (2000). Association of heterotrimeric G(i) with the insulin-like growth factor-I receptor. Release of G(betagamma) subunits upon receptor activation. J Biol Chem 275: 2255-2258. (Pubitemid 30081978)
22. Hartwell DW, Mayadas TN, Berger G, Frenette PS, Rayburn H, Hynes RO, et al,. (1998). Role of P-selectin cytoplasmic domain in granular targeting in vivo and in early inflammatory responses. J Cell Biol 143: 1129-1141. (Pubitemid 28547409)
23. He X, Chow D, Martick MM, Garcia KC, (2001). Allosteric activation of a spring-loaded natriuretic peptide receptor dimer by hormone. Science 293: 1657-1662. (Pubitemid 32807845)
24. Hobbs A, Foster P, Prescott C, Scotland R, Ahluwalia A, (2004). Natriuretic peptide receptor-C regulates coronary blood flow and prevents myocardial ischemia/reperfusion injury: novel cardioprotective role for endothelium-derived C-type natriuretic peptide. Circulation 110: 1231-1235. (Pubitemid 39202338)
25. Hutchinson HG, Trindade PT, Cunanan DB, Wu CF, Pratt RE, (1997). Mechanisms of natriuretic-peptide-induced growth inhibition of vascular smooth muscle cells. Cardiovasc Res 35: 158-167. (Pubitemid 27374753)
26. Ishida A, Sasaguri T, Miwa Y, Kosaka C, Taba Y, Abumiya T, (1999). Tumor suppressor p53 but not cGMP mediates NO-induced expression of p21(Waf1/Cip1/Sdi1) in vascular smooth muscle cells. Mol Pharmacol 56: 938-946.
27. Itoh T, Nagaya N, Murakami S, Fujii T, Iwase T, Ishibashi-Ueda H, et al,. (2004). C-type natriuretic peptide ameliorates monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med 170: 1204-1211. (Pubitemid 39577379)
28. Kanda S, Miyata Y, Mochizuki Y, Matsuyama T, Kanetake H, (2005). Angiopoietin 1 is mitogenic for cultured endothelial cells. Cancer Res 65: 6820-6827. (Pubitemid 41060720)
29. Kibbe MR, Li J, Nie S, Watkins SC, Lizonova A, Kovesdi I, et al,. (2000). Inducible nitric oxide synthase (iNOS) expression upregulates p21 and inhibits vascular smooth muscle cell proliferation through p42/44 mitogen-activated protein kinase activation and independent of p53 and cyclic guanosine monophosphate. J Vasc Surg 31: 1214-1228. (Pubitemid 30418493)
30. Kuhlencordt PJ, Rosel E, Gerszten RE, Morales-Ruiz M, Dombkowski D, Atkinson WJ, et al,. (2004). Role of endothelial nitric oxide synthase in endothelial activation: insights from eNOS knockout endothelial cells. Am J Physiol Cell Physiol 286: C1195-C1202. (Pubitemid 38506935)
31. Kuhn M, Volker K, Schwarz K, Carbajo-Lozoya J, Flogel U, Jacoby C, et al,. (2009). The natriuretic peptide/guanylyl cyclase-a system functions as a stress-responsive regulator of angiogenesis in mice. J Clin Invest 119: 2019-2030.
32. Kuhnl A, Pelisek J, Tian W, Kuhlmann M, Rolland PH, Mekkaoui C, et al,. (2005). C-type natriuretic peptide inhibits constrictive remodeling without compromising re-endothelialization in balloon-dilated renal arteries. J Endovasc Ther 12: 171-182. (Pubitemid 40517050)
33. Marra DE, Simoncini T, Liao JK, (2000). Inhibition of vascular smooth muscle cell proliferation by sodium salicylate mediated by upregulation of p21(Waf1) and p27(Kip1). Circulation 102: 2124-2130.
34. Matter CM, Rozenberg I, Jaschko A, Greutert H, Kurz DJ, Wnendt S, et al,. (2006). Effects of tacrolimus or sirolimus on proliferation of vascular smooth muscle and endothelial cells. J Cardiovasc Pharmacol 48: 286-292. (Pubitemid 46066833)
35. Mookerjee I, Hewitson TD, Halls ML, Summers RJ, Mathai ML, Bathgate RA, et al,. (2009). Relaxin inhibits renal myofibroblast differentiation via RXFP1, the nitric oxide pathway, and Smad2. FASEB J 23: 1219-1229.
36. Morishige K, Shimokawa H, Yamawaki T, Miyata K, Eto Y, Kandabashi T, et al,. (2000). Local adenovirus-mediated transfer of C-type natriuretic peptide suppresses vascular remodeling in porcine coronary arteries in vivo. J Am Coll Cardiol 35: 1040-1047. (Pubitemid 30189939)
37. Murthy KS, Makhlouf GM, (1999). Identification of the G protein-activating domain of the natriuretic peptide clearance receptor (NPR-C). J Biol Chem 274: 17587-17592.
38. Murthy KS, Teng BQ, Zhou H, Jin JG, Grider JR, Makhlouf GM, (2000). G(i-1)/G(i-2)-dependent signaling by single-transmembrane natriuretic peptide clearance receptor. Am J Physiol Gastrointest Liver Physiol 278: G974-G980. (Pubitemid 30439177)
39. Naruko T, Ueda M, van der Wal AC, van der Loos CM, Itoh H, Nakao K, et al,. (1996). C-type natriuretic peptide in human coronary atherosclerotic lesions. Circulation 94: 3103-3108. (Pubitemid 26427474)
40. Naruko T, Itoh A, Haze K, Ehara S, Fukushima H, Sugama Y, et al,. (2005). C-Type natriuretic peptide and natriuretic peptide receptors are expressed by smooth muscle cells in the neointima after percutaneous coronary intervention. Atherosclerosis 181: 241-250. (Pubitemid 41019604)
41. Nurnberg B, Gudermann T, Schultz G, (1995). Receptors and G proteins as primary components of transmembrane signal transduction. Part 2. G proteins: structure and function. J Mol Med 73: 123-132.
42. Ohno N, Itoh H, Ikeda T, Ueyama K, Yamahara K, Doi K, et al,. (2002). Accelerated reendothelialization with suppressed thrombogenic property and neointimal hyperplasia of rabbit jugular vein grafts by adenovirus-mediated gene transfer of C-type natriuretic peptide. Circulation 105: 1623-1626. (Pubitemid 34298601)
43. Olson MF, Paterson HF, Marshall CJ, (1998). Signals from Ras and Rho GTPases interact to regulate expression of p21Waf1/Cip1. Nature 394: 295-299. (Pubitemid 28335044)
44. Pagano M, Anand-Srivastava MB, (2001). Cytoplasmic domain of natriuretic peptide receptor C constitutes Gi activator sequences that inhibit adenylyl cyclase activity. J Biol Chem 276: 22064-22070.
45. Pearson G, Robinson F, Beers GT, Xu BE, Karandikar M, Berman K, et al,. (2001). Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 22: 153-183. (Pubitemid 32458157)
46. Pedram A, Razandi M, Levin ER, (1998). Extracellular signal-regulated protein kinase/Jun kinase cross-talk underlies vascular endothelial cell growth factor-induced endothelial cell proliferation. J Biol Chem 273: 26722-26728. (Pubitemid 28471688)
47. Pelisek J, Fuchs AT, Kuehnl A, Tian W, Kuhlmann MT, Rolland PH, et al,. (2006). C-type natriuretic peptide for reduction of restenosis: gene transfer is superior over single peptide administration. J Gene Med 8: 835-844. (Pubitemid 44097139)
48. Potter LR, Yoder AR, Flora DR, Antos LK, Dickey DM, (2009). Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. Handb Exp Pharmacol 191: 341-366.
49. Pumiglia KM, Decker SJ, (1997). Cell cycle arrest mediated by the MEK/mitogen-activated protein kinase pathway. Proc Natl Acad Sci USA 94: 448-452. (Pubitemid 27053653)
50. Qian JY, Haruno A, Asada Y, Nishida T, Saito Y, Matsuda T, et al,. (2002). Local expression of C-type natriuretic peptide suppresses inflammation, eliminates shear stress-induced thrombosis, and prevents neointima formation through enhanced nitric oxide production in rabbit injured carotid arteries. Circ Res 91: 1063-1069. (Pubitemid 35416644)
51. Ray RM, Zimmerman BJ, McCormack SA, Patel TB, Johnson LR, (1999). Polyamine depletion arrests cell cycle and induces inhibitors p21(Waf1/Cip1), p27(Kip1), and p53 in IEC-6 cells. Am J Physiol 276: C684-C691. (Pubitemid 29157385)
52. Rose RA, Lomax AE, Kondo CS, Anand-Srivastava MB, Giles WR, (2004). Effects of C-type natriuretic peptide on ionic currents in mouse sinoatrial node: a role for the NPR-C receptor. Am J Physiol Heart Circ Physiol 286: H1970-H1977. (Pubitemid 38525488)
53. Sato J, Nair K, Hiddinga J, Eberhardt NL, Fitzpatrick LA, Katusic ZS, et al,. (2000). eNOS gene transfer to vascular smooth muscle cells inhibits cell proliferation via upregulation of p27 and p21 and not apoptosis. Cardiovasc Res 47: 697-706.
54. Savage MP, Fischman DL, Rake R, Leon MB, Schatz RA, Penn I, et al,. (1998). Efficacy of coronary stenting versus balloon angioplasty in small coronary arteries. Stent Restenosis Study (STRESS) Investigators. J Am Coll Cardiol 31: 307-311. (Pubitemid 28153448)
55. Scotland RS, Cohen M, Foster P, Lovell M, Mathur A, Ahluwalia A, et al,. (2005). C-type natriuretic peptide inhibits leukocyte recruitment and platelet-leukocyte interactions via suppression of P-selectin expression. Proc Natl Acad Sci USA 102: 14452-14457. (Pubitemid 41429718)
56. Serrano M, Hannon GJ, Beach D, (1993). A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704-707. (Pubitemid 24036021)
57. Soeki T, Kishimoto I, Okumura H, Tokudome T, Horio T, Mori K, et al,. (2005). C-type natriuretic peptide, a novel antifibrotic and antihypertrophic agent, prevents cardiac remodeling after myocardial infarction. J Am Coll Cardiol 45: 608-616. (Pubitemid 40222257)
58. Suga S, Nakao K, Itoh H, Komatsu Y, Ogawa Y, Hama N, et al,. (1992). Endothelial production of C-type natriuretic peptide and its marked augmentation by transforming growth factor-beta. Possible existence of 'vascular natriuretic peptide system'. J Clin Invest 90: 1145-1149.
59. Tokudome T, Horio T, Soeki T, Mori K, Kishimoto I, Suga S, et al,. (2004). Inhibitory effect of C-type natriuretic peptide (CNP) on cultured cardiac myocyte hypertrophy: interference between CNP and endothelin-1 signaling pathways. Endocrinology 145: 2131-2140. (Pubitemid 38535041)
60. Ueno H, Haruno A, Morisaki N, Furuya M, Kangawa K, Takeshita A, et al,. (1997). Local expression of C-type natriuretic peptide markedly suppresses neointimal formation in rat injured arteries through an autocrine/paracrine loop. Circulation 96: 2272-2279. (Pubitemid 27425833)
61. Veale CA, Alford VC, Aharony D, Banville DL, Bialecki RA, Brown FJ, et al,. (2000). The discovery of non-basic atrial natriuretic peptide clearance receptor antagonists. Part 1. Bioorg Med Chem Lett 10: 1949-1952. (Pubitemid 30663347)
62. Villar IC, Panayiotou CM, Sheraz A, Madhani M, Scotland RS, Nobles M, et al,. (2007). Definitive role for natriuretic peptide receptor-C in mediating the vasorelaxant activity of C-type natriuretic peptide and endothelium-derived hyperpolarising factor. Cardiovasc Res 74: 515-525. (Pubitemid 46711091)
63. Wang Y, de Waard MC, Sterner-Kock A, Stepan H, Schultheiss HP, Duncker DJ, et al,. (2007). Cardiomyocyte-restricted over-expression of C-type natriuretic peptide prevents cardiac hypertrophy induced by myocardial infarction in mice. Eur J Heart Fail 9: 548-557. (Pubitemid 46702821)
64. Watanabe G, Lee RJ, Albanese C, Rainey WE, Batlle D, Pestell RG, (1996). Angiotensin II activation of cyclin D1-dependent kinase activity. J Biol Chem 271: 22570-22577. (Pubitemid 26304696)
65. Yamahara K, Itoh H, Chun TH, Ogawa Y, Yamashita J, Sawada N, et al,. (2003). Significance and therapeutic potential of the natriuretic peptides/cGMP/cGMP-dependent protein kinase pathway in vascular regeneration. Proc Natl Acad Sci USA 100: 3404-3409. (Pubitemid 36356596)
66. Yoshizumi M, Kim S, Kagami S, Hamaguchi A, Tsuchiya K, Houchi H, et al,. (1998). Effect of endothelin-1 (1-31) on extracellular signal-regulated kinase and proliferation of human coronary artery smooth muscle cells. Br J Pharmacol 125: 1019-1027. (Pubitemid 28495363)
67. Zondag GC, Postma FR, Etten IV, Verlaan I, Moolenaar WH, (1998). Sphingosine 1-phosphate signalling through the G-protein-coupled receptor Edg-1. Biochem J 330 (Pt 2): 605-609. (Pubitemid 28111951)